ABUS vs HLT · P/E 5.4, rev $6.2M vs P/E 51, rev $11.17B
Arbutus Biopharma Corp (ABUS) versus Hilton Worldwide Holdings Inc (HLT) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Hilton Worldwide Holdings Inc (HLT) is a lodging company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported HLT revenue for 2024-12-31 was $11.17B. Net income was $1.54B. Revenue was up 9.2% from 2023-12-31 to 2024-12-31. HLT currently screens at market cap $75.44B and trailing P/E 50.5.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. HLT currently screens at market cap $75.44B and trailing P/E 50.5.
Not investment advice. Open the ABUS and HLT stock pages for the full models.
Not investment advice.